Trial Profile
An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Sep 2017 Results assessing the long-term efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes, were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
- 13 Jun 2017 Long-term safety and efficacy results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 03 Jul 2016 Status changed from active, no longer recruiting to completed.